Glucose-6-phosphate Dehydrogenase Deficiency: A Review
Keywords:Glucosephosphate dehydrogenase deficiency, Haemolytic anaemia, Neonatal jaundice, Erythrocytes
Deficiency of glucose-6-phosphate dehydrogenase enzyme is a common X-linked disorder that affects humans globally. It was first identified in the 1950s as a disorder that primarily affects the red blood cells causing a myriad of symptoms including acute haemolytic anaemia, neonatal jaundice and chronic nonspherocytic haemolytic anaemia. The deficiency has been extensively studied and especially in the last 5 years there have been improvements in the diagnosis and management. Various methods of diagnosis exist, however recent research focusses on the use of biosensors for more accurate and less time-consuming diagnosis. Guidelines suggest on controlling symptomology as there exists no specific treatment. Neonatal jaundice is a common complication of the disease and research on phototherapy has proved to show some effect in managing this condition. In the last year, protein-protein interactions have been studied and are used as a target to enhance enzyme stability and activity. AG1 is a small molecule activator that has demonstrated effectiveness in treating G6PD deficiency in models. The purpose of this review is to summarize existing literature and potential areas of research on glucose-6-phosphate dehydrogenase deficiency including clinical characteristics, diagnosis and management.
2. Lo, E., Zhong, D., Raya, B., Pestana, K., Koepfli, C., & Lee, M. C. (2019). Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia. Malaria Journal, 1–10. https://doi.org/10.1186/s12936-019-2981-x
3. Belfield, K. D., & Pharm, D. (2018). Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency, 75(3), 97–104. https://doi.org/10.2146/ajhp160961
4. Lee, M. H., Malloy, C. R., Corbin, I. R., & Jin, E. S. (2019). Assessing the pentose phosphate pathway using [ 2 , 3 ? 13 C 2 ] glucose, (February), 1–10. https://doi.org/10.1002/nbm.4096
5. Mason, P. J., Bautista, M., & Gilsanz, F. (2007). G6PD deficiency: the genotype-phenotype association, 267–283. https://doi.org/10.1016/j.blre.2007.05.002
6. Drousiotou, A., Touma, E. H., Andreou, N., Loiselet, J., Angastiniotis, M., Verrelli, B. C., & Tishkoff, S. A. (2004). Molecular characterization of G6PD deficiency in Cyprus, 33, 25–30. https://doi.org/10.1016/j.bcmd.2004.03.004
7. Harcke, S. J., Rizzolo, D., & Harcke, H. T. (2019). G6PD deficiency: An update, 21–26. https://doi.org/10.1097/01.JAA.0000586304.65429.a7
8. Luzzatto, L., & Seneca, E. (n.d.). G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. https://doi.org/10.1111/bjh.12665
9. Hecker, P. A., Leopold, J. A., Gupte, S. A., Recchia, F. A., & Stanley, W. C. (2020). Impact of glucose-6-phosphate dehydrogenase deficiency on the pathophysiology of cardiovascular disease. https://doi.org/10.1152/ajpheart.00721.2012
10. Finley, D. S. (2008). Stuttering Priapism: Report of a Case, 2963–2966. https://doi.org/10.1111/j.1743-6109.2008.01007.x
11. Persico, M. G., Viglietto, G., Martini, G., Toniolo, D., Moscatelli, C., Dono, R., Luzzatto, L. (1986), Isolation of human glucose-6-phosphate dehydrogenase (G6PD) cDNA clones: primary structure of the protein and unusual 5’ non-coding region. Nucleic Acids Research, 14(6), 2511–2522.
12. World Health Organization Working Group. Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group. Bull World Health Organ 67: 601–611, 1989.
13. Naylor C.E., Rowland P., Basak A.K., Gover S., Mason P.J., Bautista J.M., Vuilliamy T.J., Luzzatto L., Adams, M. J. (1996). Glucose 6-Phosphate Dehydrogenase Mutations Causing Enzyme Deficiency in a Model of the Tertiary Structure of the Human Enzyme, 87(7), 2974–2982.
14. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371(9606):64?74. doi:10.1016/S0140-6736(08)60073-2
15. Roper, D., Layton, M., Rees, D., Lambert, C., Vulliamy, T., Salle, B. De, & Souza, C. D. (n.d.). Laboratory diagnosis of G6PD deficiency. A British Society for Haematology Guideline. https://doi.org/10.1111/bjh.16366
16. Takizawa T, Huang IY, Ikuta, T, Yoshida A, (1986). Human glucose-6-phosphate dehydrogenase: Primary structure and cDNA cloning, 83(June), 4157–4161.
17. Deficiency, G. P. D., Gonz, A., Vanoye-carlo, A., & Hern, B. (2017). Functional and Biochemical Analysis of. https://doi.org/10.3390/catal7050135
18. Doss CG, Alasmar DR, Bux DI, Sneha P, Bakhsh FD, Al?Azwani I, et al. Genetic epidemiology of glucose?6?phosphate dehydrogenase defi? ciency in the Arab World. Sci Rep. 2016;6:37284.
19. Sarker SK, Islam MT, Eckhoff G, Hossain MA, Qadri SK, Muraduzzaman AK, et al. Molecular analysis of glucose?6?phosphate dehydrogenase gene mutations in Bangladeshi Individuals. PLoS One. 2016;11:e0166977.
20. Beutler E. G6PD deficiency. Blood. 1994;84:3613–36.
21. Beijtler, E., & Valentine, W. N. (1979). International Committee for Standardization in Haematology?: Recommended Screening Test for Glucose-6-Phosphate Dehydrogenase ( G-6-PD ) Deficiency, 465–467.
22. Tantular, I. S., & Kawamoto, F. (2003). An improved, simple screening method for detection of glucose-6-phosphate dehydrogenase deficiency, 8(6), 569–574.
23. Bancone, G., Kalnoky, M., Chu, C. S., Chowwiwat, N., Malleret, B., Pornpimon, W., Nosten, F. (2017). The G6PD flow-cytometric assay is a reliable tool for diagnosis of G6PD deficiency in women and anaemic subjects, (August), 1–8. https://doi.org/10.1038/s41598-017-10045-2
24. Aysun Adan, Gu?nel Alizada, Yag?mur Kiraz, Yusuf Baran & Ayten Nalbant (2017) Flow cytometry: basic principles and applications, Critical Reviews in Biotechnology, 37:2, 163-176, DOI: 10.3109/07388551.2015.1128876
25. Bancone G, Gornsawun G, Chu CS, Porn P, Pal S, Bansil P, et al. (2018) Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood. PLoS ONE 13(5): e0196716. https://doi.org/ 10.1371/journal.pone.0196716
26. Tracts, H., Ley, B., Alam, M. S., Donnell, J. J. O., Hossain, S., Kibria, M. G., … Richards, J. S. (2017). RESEARCH ARTICLE A Comparison of Three Quantitative Methods to Estimate G6PD Activity in the Chittagong, 1–13. https://doi.org/10.1371/journal.pone.0169930
27. Minucci, A., Gentile, L., Zuppi, C., Giardina, B., & Capoluongo, E. (2012). Clinica Chimica Acta. Clinica Chimica Acta, 413(11–12), 1018–1019. https://doi.org/10.1016/j.cca.2012.01.032
28. Ben-Joseph E.P. (2018) G6PD Deficiency, Available at: https://kidshealth.org/en/parents/g6pd.html (Accessed: 20th February 2020).
29. Tan, K. L. (2020). Phototherapy for Neonatal Jaundice in Erythrocyte Infants mean.
30. Stokowski, L. A. (2006). Fundamentals of phototherapy for neonatal jaundice. Advances in Neonatal Care: Official Journal of the National Association of Neonatal Nurses, 6(6), 303–312. https://doi.org/10.1016/j.adnc.2006.08.004
31. Itoh S., Okada H., Kuboi T., Kusaka, T. (2017). Phototherapy for neonatal hyperbilirubinemia, 959–966. https://doi.org/10.1111/ped.13332
32. Wickremasinghe, A. C., Kuzniewicz, M. W., & Grimes, B. A. (2015). Neonatal Phototherapy and Infantile Cancer, 137(6). https://doi.org/10.1542/peds.2015-1353
33. Newman, T. B., Wickremasinghe, A. C., & Walsh, E. M. (2015). Retrospective Cohort Study of Phototherapy and Childhood Cancer in Northern California, 137(6).
34. Ngoc Le, T., Reese, J. (2017). Bronze Baby Syndrome. The Journal of Pediatrics, 188, 301–301.e1. https://doi.org/10.1016/j.jpeds.2017.05.005
35. Kopelman AE, Brown RS, Odell GB. The “bronze” baby syndrome: a complication of phototherapy. J Pediatr 1972; 81:466-72.
36. Raub, A. G., Hwang, S., Horikoshi, N., Cunningham, A. D., Rahighi S., Wakatsuki S., Mochly-Rosen D. (2019). Small-Molecule Activators of Glucose-6-phosphate Dehydrogenase (G6PD) Bridging the Dimer Interface, 92618, 1321–1324. https://doi.org/10.1002/cmdc.201900341
37. Hwang, S., Mruk, K., Rahighi, S., Raub, A. G., Chen, C. H., Dorn, L. E., Horikoshi, N., Wakatsuki, S., Chen, J. K., & Mochly-Rosen, D. (2018). Correcting glucose-6-phosphate dehydrogenase deficiency with a small-molecule activator. Nature communications, 9(1), 4045. https://doi.org/10.1038/s41467-018-06447-z
How to Cite
Authors who publish with this journal agree to the following terms:
- The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
- Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
- The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
- Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
- The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
- Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
- The Author represents and warrants that:
- the Work is the Author’s original work;
- the Work is not pending review or under consideration by another publisher;
- the Work has not previously been published;
- the Work contains no libel, invasion of privacy, or other unlawful matter.
- The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.
Enforcement of copyright
The IJMS takes the protection of copyright very seriously.
If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.
If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to firstname.lastname@example.org
If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to email@example.com